Abstract
Dilated cardiomyopathy (DCM) is predominantly diagnosed according to echocardiographic features that include left ventricular or biventricular dilation and reduced systolic function. Current classification schemes from major heart societies exclude primary ischemic heart disease or abnormal loading conditions (such as hypertension or valvular disease) that may cause a similar impairment in global systolic function. Clinically, the term ischemic cardiomyopathy is frequently used to refer to the myocardial dysfunction caused by coronary artery disease (see Chapter 20 ) and is a leading cause of heart failure in the developed world. Whereas significant valvular disease is usually readily apparent on echocardiography, the exclusion of ischemic heart disease causing secondary left ventricular (LV) failure requires additional investigation, since the regional wall motion abnormalities suggestive of ischemic heart disease can also be noted in DCM. Many of the underlying diseases such as myocarditis, tachycardia-induced cardiomyopathy, peripartum cardiomyopathy (PPCM), as well as toxic-metabolic and other diseases with multiorgan system involvement ( Box 22.1 ) share a similar end-stage phenotype characterized by left ventricular dilatation, reduced systolic function, and other common features that will be covered here. Other types of DCM ( Box 22.2 ) such as Takotsubo cardiomyopathy, arrhythmogenic cardiomyopathy (ACM), noncompaction, and sarcoidosis typically manifest more disease-specific features in addition to overall LV dilatation. In addition, overlap of the aforementioned underlying etiologies may occur in a single patient, and a precisely defined diagnosis may occasionally only be revealed by genetic testing.
DCM is a chronic disease that requires follow-up of the structural changes and functional impairment of the heart. Some of these cardiomyopathies, notably Takotsubo, tachycardia-mediated, and postpartum states, can improve and even resolve completely with treatment and/or time. In the context of the clinical status of the patient and the patient’s comorbidities, echocardiography often plays a crucial role in guiding further management of patients with DCM and their prognostication.
Keywords
dilated cardiomyopathy, left ventricular noncompaction, arrhythmogenic cardiomyopathy, tachycardia-induced cardiomyopathy, peripartum cardiomyopathy
Introduction
Dilated cardiomyopathy (DCM) is predominantly diagnosed according to echocardiographic features that include left ventricular or biventricular dilation and reduced systolic function. Current classification schemes from major heart societies exclude primary ischemic heart disease or abnormal loading conditions (such as hypertension or valvular disease) that may cause a similar impairment in global systolic function. Clinically, the term ischemic cardiomyopathy is frequently used to refer to the myocardial dysfunction caused by coronary artery disease (see Chapter 20 ) and is a leading cause of heart failure in the developed world. Whereas significant valvular disease is usually readily apparent on echocardiography, the exclusion of ischemic heart disease causing secondary left ventricular (LV) failure requires additional investigation, since the regional wall motion abnormalities suggestive of ischemic heart disease can also be noted in DCM. Many of the underlying diseases such as myocarditis, tachycardia-induced cardiomyopathy, peripartum cardiomyopathy (PPCM), as well as toxic-metabolic and other diseases with multiorgan system involvement ( Box 22.1 ) share a similar end-stage phenotype characterized by left ventricular dilatation, reduced systolic function, and other common features that will be covered here. Other types of DCM ( Box 22.2 ) such as Takotsubo cardiomyopathy, arrhythmogenic cardiomyopathy (ACM), noncompaction, and sarcoidosis typically manifest more disease-specific features in addition to overall LV dilatation. In addition, overlap of the aforementioned underlying etiologies may occur in a single patient, and a precisely defined diagnosis may occasionally only be revealed by genetic testing.
Infectious myocarditis (viral including HIV, Chagas, Lyme)
Peripartum
Tachycardia-mediated
Drugs (most common: chemotherapeutics)
Toxins and overload: excess alcohol intake; cocaine, amphetamines, ecstasy (MDMA); iron overload
Nutritional deficiency (e.g., carnitine, selenium, thiamine, zinc, copper deficiencies)
Endocrinologic disorders (hypo- and hyperthyroidism, diabetes mellitus, Cushing/Addison disease, pheochromocytoma, acromegaly)
Immune-mediated diseases: systemic lupus erythematosus (SLE), antiheart antibodies (AHA), Kawasaki disease, Churg-Strauss syndrome
Neuromuscular disorders (e.g., Duchenne/Becker, Emery-Dreifuss muscular dystrophies)
Mitochondrial disorders
HIV , Human immunodeficiency virus; MDMA , 3,4-Methylenedioxymethamphetamine.
Arrhythmogenic cardiomyopathy
Takotsubo (stress) cardiomyopathy
Left ventricular noncompaction
Sarcoidosis
DCM is a chronic disease that requires follow-up of the structural changes and functional impairment of the heart. Some of these cardiomyopathies, notably Takotsubo, tachycardia-mediated, and post-partum states, can improve and even resolve completely with treatment and/or time. In the context of the clinical status of the patient and the patient’s comorbidities, echocardiography often plays a crucial role in guiding further management of patients with DCM and their prognostication.
Introduction
Dilated cardiomyopathy (DCM) is predominantly diagnosed according to echocardiographic features that include left ventricular or biventricular dilation and reduced systolic function. Current classification schemes from major heart societies exclude primary ischemic heart disease or abnormal loading conditions (such as hypertension or valvular disease) that may cause a similar impairment in global systolic function. Clinically, the term ischemic cardiomyopathy is frequently used to refer to the myocardial dysfunction caused by coronary artery disease (see Chapter 20 ) and is a leading cause of heart failure in the developed world. Whereas significant valvular disease is usually readily apparent on echocardiography, the exclusion of ischemic heart disease causing secondary left ventricular (LV) failure requires additional investigation, since the regional wall motion abnormalities suggestive of ischemic heart disease can also be noted in DCM. Many of the underlying diseases such as myocarditis, tachycardia-induced cardiomyopathy, peripartum cardiomyopathy (PPCM), as well as toxic-metabolic and other diseases with multiorgan system involvement ( Box 22.1 ) share a similar end-stage phenotype characterized by left ventricular dilatation, reduced systolic function, and other common features that will be covered here. Other types of DCM ( Box 22.2 ) such as Takotsubo cardiomyopathy, arrhythmogenic cardiomyopathy (ACM), noncompaction, and sarcoidosis typically manifest more disease-specific features in addition to overall LV dilatation. In addition, overlap of the aforementioned underlying etiologies may occur in a single patient, and a precisely defined diagnosis may occasionally only be revealed by genetic testing.
Infectious myocarditis (viral including HIV, Chagas, Lyme)
Peripartum
Tachycardia-mediated
Drugs (most common: chemotherapeutics)
Toxins and overload: excess alcohol intake; cocaine, amphetamines, ecstasy (MDMA); iron overload
Nutritional deficiency (e.g., carnitine, selenium, thiamine, zinc, copper deficiencies)
Endocrinologic disorders (hypo- and hyperthyroidism, diabetes mellitus, Cushing/Addison disease, pheochromocytoma, acromegaly)
Immune-mediated diseases: systemic lupus erythematosus (SLE), antiheart antibodies (AHA), Kawasaki disease, Churg-Strauss syndrome
Neuromuscular disorders (e.g., Duchenne/Becker, Emery-Dreifuss muscular dystrophies)
Mitochondrial disorders
HIV , Human immunodeficiency virus; MDMA , 3,4-Methylenedioxymethamphetamine.
Arrhythmogenic cardiomyopathy
Takotsubo (stress) cardiomyopathy
Left ventricular noncompaction
Sarcoidosis
DCM is a chronic disease that requires follow-up of the structural changes and functional impairment of the heart. Some of these cardiomyopathies, notably Takotsubo, tachycardia-mediated, and post-partum states, can improve and even resolve completely with treatment and/or time. In the context of the clinical status of the patient and the patient’s comorbidities, echocardiography often plays a crucial role in guiding further management of patients with DCM and their prognostication.
Common Features of Dilated Cardiomyopathies
Left Ventricular Dilation and Systolic Functional Impairment
The principal hallmark of DCM is left ventricular cavity dilation , although enlargement of other cardiac chambers also often occurs. Left ventricular cavity enlargement is usually quantified by measuring increased LV end-diastolic and end-systolic dimensions and volumes. Although the myocardial walls may be either of normal thickness or thinned, the total left ventricular mass is increased due to the overall increase in LV size. Furthermore, measures of LV systolic function such as fractional shortening, ejection fraction, stroke volume, and cardiac output are typically reduced ( Fig. 22.1 ).
It should be emphasized that, although the stroke volume is reduced in most cases, LV cavity dilation may initially serve to compensate by restoring stroke volume (measured on echocardiography as the difference between the LV end-diastolic and end-systolic volume). Namely, a larger ventricle can eject much more volume than a smaller one, even with the same amount of contraction (i.e., segmental deformation) ( Fig. 22.2 ). Hence, the final cardiac output may be initially preserved despite impairment in ejection fraction (measured as the stroke volume divided by LV end-diastolic volume). Restoration of stroke volume by ventricular dilatation is an integral part of the process of LV remodeling in the adaptation to changes in contractility and loading conditions. Thus, (1) in DCM, although inherent myocardial dysfunction and diminished myocardial contractility is the primary defect, ventricular dilation may enable the generation of the same amount of stroke volume with less deformation, and (2) in volume overload states (e.g., valvular regurgitation, such as functional mitral regurgitation), an increased amount of stroke volume is required and may be generated (with the same amount of contractility) by an LV that dilates to adapt (see Fig. 22.2 ). Indeed, preservation of stroke volume (as well as an increase in heart rate) to maintain overall cardiac output may explain why the severity of symptoms can remain relatively low despite notably impaired left ventricular ejection fraction (LVEF), despite the fact that the latter correlates strongly with prognosis. Conversely, symptoms of congestive heart failure are more directly related to elevated LV filling pressures (see below). Fig. 22.1 and provide an example of two patients with severely dilated left ventricles and severely reduced LVEF but different LV stroke volumes, atrial sizes, and functional class.
Based on the described principles of remodeling, the left ventricular shape changes with disease progression from the typical elongated shape to a more globular one. A simple measurement that can quantify this is the sphericity index , defined as the ratio of the LV length and width ( Fig. 22.3 ). A normal sphericity index is greater than 1.6; in DCM, this is generally reduced , implying pathologic remodeling with notable cavity dilation (see also Fig. 20.5 in Chapter 20 ).
Several features of DCM are manifest and quantifiable on m-mode echocardiography (see Chapter 2 ): LV and right ventricular (RV) cavity enlargement, changes in wall thickness and calculated LV mass, as well as reduced segmental wall thickening are classically recognizable on m-mode as signs of LV dilation and poor systolic performance. Poor aortic valve opening with premature closure can be noted in the setting of reduced stroke volume. Due to LV dilatation, the mitral leaflet echoes are often distanced to greater than 1.0 cm of the mitral E-point from the interventricular septum (see Fig. 2.16 ). A characteristic pattern of decreased mitral leaflet opening and an occasional “b-notch” indicative of markedly elevated LV end-diastolic pressure are shown in Fig. 2.15 in Chapter 2 . Impairment in LV systolic function can also be assessed on apical windows by reduced mitral annular planar systolic excursion (MAPSE) ( Fig. 22.4 ). A MAPSE less than 10 mm (usually averaged from 2 to 4 point measurements spaced around the mitral annulus) is indicative of reduced longitudinal LV motion.
Similarly to reduced MAPSE, impaired motion of the base of the heart towards the more stationary apex (expressing the longitudinal function of the LV) can be quantified by Doppler Tissue Imaging S’ (systolic) velocity or more advanced parameters of myocardial deformation, such as systolic strain, which is often expressed as global longitudinal strain ( Fig. 22.5 ) or less frequently as systolic strain-rate (see Chapter 6 ), all of which will typically be reduced in DCM.
Finally, Doppler echocardiography may be used in the hemodynamic assessment of LV systolic function: in addition to volumetric measurements of stroke volume and cardiac output, these calculations can also be performed using the continuity of flow equation (see Chapter 1 ). Multiplication of the cross-sectional area and the time velocity integral of the left ventricular outflow tract (LVOT) will provide the calculation of left ventricular stroke volume ( Fig. 22.6 ), which is typically reduced in advanced DCM. The change of pressure over time (d P /d t ) can be measured when a sufficient mitral regurgitation envelope (recorded by continuous wave Doppler) is present and will also be reduced in most patients with DCM ( Fig. 22.7 ). This noninvasive parameter has shown good correlation with values measured by cardiac catheterization and has been associated with worse prognosis when less than 600 mm Hg/s. For more details on the assessment of LV systolic function, please refer to Chapter 14 .